As CEO of the Victoria Hand Project, a charity spun out of the University of Victoria in British Columbia, Michael Peirone is a jack of all trades: engineering, operations, IP, business strategy, fundraising and...
Monogram Orthopedics (NASDAQ:MGRM) is working to advance the standard of care with its next-generation robot and 3D-printed implants that match a patient's precise anatomy, decreasing the number of incisions and bone...
Closely-held Cantex Pharmaceuticals has an extensive Phase 2 program underway with its lead drug candidate, azeliragon, in breast cancer, pancreatic cancer, brain metastasis and glioblastoma, well as in prevention of...
Chinook Therapeutics (NASDAQ:KDNY), which is developing three drug candidates to change the course of kidney care as well as a precision medicine pipeline of R&D programs, received a shot in the arm this month when...
Centessa Pharmaceuticals (NASDAQ:CNTA) is developing a portfolio of innovative drug candidates with small, focused R&D teams, a model it calls “asset-centric.”
ZyVersa Therapeutics (NASDAQ: ZVSA) is advancing two proprietary technologies to develop multiple, potentially transformative drugs for underserved patients with renal and inflammatory diseases.
John Coleman, Ph.D., envisions a future where blood types cease to be a primary constraint in life-saving organ transplants and blood transfusions. “Recognizing the urgent need for solutions to these challenges, we have...
Virax Biolabs (NASDAQ:VRAX) expects to begin in the third quarter a clinical performance study of its proprietary T-Cell testing platform, ViraxImmune, as a stepping stone for regulatory compliance in the U.S. and...
HDT Bio is developing messenger RNA vaccines addressing diverse indications in infectious diseases and oncology, and is utilizing regional partnerships for manufacturing, clinical development and commercialization.
Closely-held ADvantage Therapeutics is awaiting regulatory approval in Europe to proceed with a Phase 2b confirmatory clinical trial of its lead drug candidate, AD04, for the treatment of mild Alzheimer’s disease (AD).